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PENILAIAN EKONOMI DAN KUALITI HIDUP BERKAITAN KESIHATAN 
PESAKIT TUBERKULOSIS DI YEMEN 
 
ABSTRAK 
Kajian ini bertujuan untuk mengakses aspek ekonomi dan kualiti hidup berkaitan 
kesihatan pesakit tuberkulosis di Yemen.  Kajian berbentuk keratan lintang dan 
prospektif telah dijalankan dalam kalangan pesakit-pesakit tuberkulosis pulmonari dan 
ekstra-pulmonari yang telah didiagnosis dan dirawat di pusat TB di Sana’a, ibu kota 
Yemen.  Data sosio-demografik, klinikal dan makmal serta jenis regimen ubat yang 
digunakan dalam rawatan dikumpulkan daripada pesakit TB dan rekod perubatan di 
pusat TB.  Metodologi farmakoekonomi telah diaplikasi untuk mengira kos langsung 
dan tidak langsung.  Pesakit diminta untuk melengkapkan soal selidik DR-12.  Pesakit 
perlu mengisi soal selidik tersebut pada permulaan rawatan, selepas satu bulan dan 
diulangi pada akhir fasa rawatan intensif.  Nisbah wanita kepada lelaki adalah 1.2 dan 
1.6 masing-masing bagi tuberkulosis pulmonari dan ekstra pulmonari.  Umur median 
pesakit tuberkulosis pulmonari adalah 29 dan 30 bagi pesakit tuberkulosis ekstra 
pulmonari.  Kajian ini mendapati bahawa bilangan pesakit tuberkulosis ekstra pulmonari 
yang didiagnosis di hospital swasta dan klinik (41%) adalah lebih tinggi berbanding 
pesakit tuberkulosis pulmonari (26%).  Kos-kos perubatan langsung, bukan perubatan 
langsung dan tidak langsung bagi TB pulmonari adalah masing-masing US 30.07, US$ 
36.94 dan US$ 73.10.  Manakala bagi TB ekstra pulmonari adalah masing-masing US$ 
32.71, US$ 99.90 dan US$ 51.90.  Kos yang ditanggung oleh pesakit TB pulmonari dan 
 xxii 
ekstra pulmonari adalah masing-masing sekitar 76.1% dan 89.4% daripada kos 
keseluruhan rawatan.  TB pulmonari menunjukkan skor HRQoL yang lebih buruk 
berbanding dengan TB ekstra pulmonari (P<0.05).  Perbezaan yang paling besar dilihat 
pada dimensi yang mencerminkan simptom semasa fasa intensif.  Penambahbaikan pada 
HRQoL kedua-dua pesakit pulmonari dan ekstra pulmonari bagi ketiga-tiga domain 
selepas satu bulan rawatan dan akhir fasa intensif adalah signifikan secara statistik 
(P<0.001), bagi setiap kumpulan apabila dibandingkan dengan masa awal. Secara 
kesimpulan, kajian ini menunjukkan bilangan wanita dan pesakit muda adalah lebih 
tinggi bagi kedua-dua TB pulmonari dan ekstra pulmonari.  Bilangan pesakit ekstra 
pulmonari yang didiagnosis di hospital swasta dan klinik adalah lebih tinggi berbanding 
dengan pesakit TB pulmonari.  Pesakit ekstra pulmonari berpendapatan bulanan lebih 
rendah berbanding dengan TB pulmonari.  Daripada perspektif perkhidmatan kesihatan 
dan pesakit, kos bagi terapi TB pulmonari adalah masing-masing 23.9% dan 76.1%, 
manakala kos bagi TB ekstra pulmonari adalah masing-masing 10.6% dan 89.4%.  
Dalam kajian HRQoL, pada permulaan terapi, pesakit TB pulmonari secara signifikan 
mempunyai HRQoL yang lebih rendah berbanding dengan pesakit TB ekstra pulmonari. 
Kedua-dua pesakit TB pulmonari dan ekstra pulmonari secara signifikan bertambah baik 
selepas masa awal rawatan. Pesakit TB pulmonari yang bertukar bertambah baik dari 
segi simptom berbanding dengan pesakit TB pulmonari yang tidak bertukar. 
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ECONOMIC AND HEALTH RELATED QUALITY OF LIFE EVALUATION 
OF TUBERCULOSIS PATIENTS IN YEMEN 
 
ABSTRACT 
The study aims to assess the economic and the health related quality of life for 
tuberculosis patients in Yemen. A Cohort prospective study was carried out among 
pulmonary tuberculosis and extra pulmonary tuberculosis patients diagnosed and treated 
in a TB centers in Sana’a, the capital city of Yemen. Socio demographic, clinical and 
laboratory data and types of drug regimen used in treatment were collected from TB 
patients and medical records at the TB centers.  Pharmacoeconomic methodology was 
applied to calculate direct and indirect costs. The patients were asked to complete DR-
12 questionnaire. The patients was subjected to the questionnaire at onset of treatment, 
then after one month and finally repeated at the end of intensive phase of treatment.  The 
female to male ratio was 1.2 and 1.6 for pulmonary tuberculosis and extra pulmonary 
tuberculosis, respectively. The median age for pulmonary tuberculosis patients was 29 
and 30 years for extra pulmonary tuberculosis patients. This study found the extra 
pulmonary tuberculosis patients diagnosed in private hospital and clinics (41%) were 
more than pulmonary tuberculosis patients (26%). The direct medical, direct non-
medical and indirect costs for pulmonary TB were US$ 30.07, US$ 36.94 and US$ 
73.10, respectively. While for extra pulmonary TB, the costs were US$ 32.71, US$ 
99.90 and US$ 51.90, respectively. Of the total costs of treatment, the cost for 
 xxiv 
pulmonary TB and extra pulmonary TB patients constitutes approximately 76.1% and 
89.4%, respectively. 
Pulmonary TB had significantly worse HRQoL score compared to extra pulmonary TB 
(P<0.017). The greatest difference was observed in the dimension reflecting symptoms, 
during the intensive phase. The improvement in HRQoL for both pulmonary and extra 
pulmonary patients for the three domains, after one month of treatment and at the end of 
intensive phase were statistically significant (P< 0.001), for each group compared to the 
base line.  In conclusion, this research showed that, female and younger ages were 
higher in both extra pulmonary and pulmonary TB. The extra pulmonary TB patients 
diagnosed in private hospital and clinics were higher than pulmonary TB patients. The 
extra pulmonary have less monthly income than pulmonary TB. 
From the perspectives of the health services and patients, the total cost for pulmonary 
TB therapy were 23.89 % and 76.11%, respectively, while the total cost for extra 
pulmonary TB were 10.6% and 89.4%, respectively. The cost of anti-TB drugs 
constitutes the highest proportion of the costs to the public health services, 38.1% and 
78.0% for pulmonary and extra pulmonary TB, respectively.  In HRQoL study, at the 
beginning of therapy, pulmonary TB patients have significantly lower HRQoL than 
extra pulmonary tuberculosis patients. Both pulmonary and extra pulmonary TB patients 
are significantly improved after onset of treatment. The converted pulmonary TB 
patients improved in symptoms as compared to the non converted pulmonary TB 
patients.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Overview 
Mycobacterium Tuberculosis (TB) is an infectious communicable disease which is a 
major cause of death in the world (WHO, 2007). There are two principle kinds of TB: 
pulmonary TB, which usually attacks the lungs, and extra-pulmonary TB, which attacks 
any part of the body, such as: the lymphatic, pleura, bone and/or joint, genitourinary 
tract, miliary, peritoneal, meninges and/or central nervous system (CNS); and all organ 
systems that may be affected. Sometimes patients suffer from both pulmonary TB 
combined with extra pulmonary TB (Parimon et al., 2008; Sreeramareddy et al., 2008; 
Mario et al., 2008). 
 
Mycobacterium Tuberculosis is most transmitted from a person with infectious 
pulmonary tuberculosis to others by droplet nuclei through cough, sneeze, or speak. 
Furthermore, having close contacts to the infected persons, intense, duration, or repeated 
contacts are considered among the major routes to infect with TB. Other resources 
include: foreign-born from endemic area with TB, residents and employees living in 
congregated areas, health care workers who work with severely infected patients, low-
income populations, racial or ethnic minority populations, children in contact with 
severely infected adults, and finally persons who inject illicit drugs (American Thoracic 
Society, 1999; Smith and Moss, 1994; Verver et al., 2004;   Palomino et al., 2007).  
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Extra pulmonary TB that occurs outside the lungs may spread through lymphatic or 
hematogenous dissemination to any tract or through coughing and swallowing to the 
gastrointestinal tract. Such type of bacteria may stay latent for years at a particular site 
before causing the illness. Nearly all organs of the body can be influenced by extra 
pulmonary TB; it has a wide variety of clinical manifestations; therefore making it less 
familiar to most of clinicians and delay of diagnosis (Beek et al., 2006; Gonzalez et al., 
2003). 
 
 Extra pulmonary TB, is more often diagnosed in women and young patients; extra 
pulmonary tuberculosis is seen more commonly today than in the past (Mario et al., 
2008; Aaron et al., 2004; Rieder et al., 1990; Gonzalez et al., 2003; Yang et al., 2004; 
Noertjojo et al., 2002; Cowie and Sharpe, 1998; Antony et al., 1995; Chan-Yeung et al., 
2002). In the United States, extra pulmonary TB is associated with ethnic minorities and 
those born in other countries (Rieder et al., 1990) while in Asia origin, lymphatic TB 
occupies the front position of the risky infectious diseases (Cowie and Sharpe, 1997, 
1998; Moudgil and Leitch, 1994; Nisar et al., 1991; Ormerod, et al., 1991). A study of 
Somali TB patients in Minnesota demonstrated frequent lymphatic TB (Kempainen et 
al., 2001).  
 
1.2 Epidemiology of Tuberculosis in Yemen 
Tuberculosis is still one of the major problems in Yemen. Yemen is considered as one of 
the high-burden countries in the region for a long time based on the evaluation of TB 
which has been conducted by National-Wide Survey of the Tuberculin Testing among 
children school (AL-Absi, 2007).  TB is ranked 4
th
 in the list of priority public health 
 3 
problems. It is also estimated that TB is the 4
th
 cause of death based on hospital statistics 
(TB guide, 2010). The annual expected incidence of new pulmonary TB smear-positive 
(NSS+) is 8480, and equal number of other forms of TB was estimated. The most recent 
estimates of TB in Yemen show that the annual incidence of new pulmonary TB smear-
positive cases is 37 per 100,000 population, which means that, 7297 new pulmonary TB 
smear-positive cases per year would be expected in Yemen, and 8874 for other forms of 
TB cases; estimated 45 per 100,000 populations. Sana’a, the capital city of Yemen, 
occupied the first province with extra pulmonary TB cases and has the second highest 
number of cases of all forms of TB as compared to other provinces (AL-Absi, 2007).  
Table 1.1 below shows the trend of Case-Finding of tuberculosis in Yemen during 1995-
2007 
 
Table 1.2 illustrated the distribution of tuberculosis among Yemen governorates for the 
Year 2007. From the report, the city of Sana’a had the highest number of cases for 
pulmonary and extra pulmonary diseases compared to other governorates. The majority 
of tuberculosis patients in Yemen were between 15-54 years old, as shown in Figure 1.1. 
The report also showed that pulmonary tuberculosis is represented by 72% of the 
patients while the extra pulmonary tuberculosis represented 28%; most of them from 
Sana’a city (AL-Absi, 2007). 
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Table 1.1: All types of Tuberculosis in Yemen during 1995-2007(adapted from AL-
Absi, 2007) 
Years New P.Sm+ Relapses New P.Sm- EP Total 
1995 3681 375 7390 3082 14528 
1996 4371 298 7280 2415 14364 
1997 4717 344 4251 2695 12007 
1998 4896 297 4323 2867 12383 
1999 5427 475 3824 3301 13027 
2000 5565 440 4176 3470 13651 
2001 4968 584 4383 3094 13029 
2002 4259 436 4188 2794 11677 
2003 3793 426 3435 2759 10413 
2004 3434 377 3473 2732 10016 
2005 3379 351 2780 2553 9063 
2006 3337 311 2531 2559 8738 
2007 3537 325 2196 2369 8427 
Note: New P.Sm+ refers to new pulmonary TB smear-positive; New P.Sm- refers to new 
pulmonary TB smear-negative; EP refers to extra pulmonary TB. 
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Table 1.2: All types of Tuberculosis in Yemen Governorates for the Year 2007 
(adapted from AL-Absi, 2007) 
Governorates New P.Sm+ Relapses New P.Sm- EP Total 
Abyan 123 15 89 38 265 
Aden 287 39 133 172 731 
Al-Baidha 68 4 35 33 93 
Al-Dhalea 61 4 24 54 143 
Al-Hodeida  704 58 165 244 1170 
Al-Jawf 112 4 52 30 198 
Al-Mahra 32 4 51 7 94 
Al-Mahweet 41 6 47 38 132 
Al-Mukalla 113 19 17 19 168 
Amran 80 3 59 53 195 
Dhamar 213 20 145 155 533 
Hajjah 275 27 397 132 813 
Ibb 194 10 21 111 336 
Lahj 142 21 132 106 401 
Mareb 50 2 37 38 127 
Saadah 52 2 33 25 112 
Sana'a city 313 39 261 570 1193 
Sana'a Gov. 77 3 80 65 225 
Sayioun  24 2 17 22 65 
Shabwah 29 4 47 14 94 
Taiz 508 38 241 433 1220 
Raimah 39 1 14 18 72 
Total 3537 325 2196 2369 8427 
Note: New P.Sm+ refers to new pulmonary TB smear-positive; New P.Sm- refers to new 
pulmonary TB smear-negative;  EP refers to extra pulmonary TB; Sana'a Gov. refer to Sana’a 
governorate. 
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Figure 1.1 Age Distribution of Tuberculosis Patients in Yemen in the year 2007 
(adapted from AL-Absi, 2007) 
1.3 Transmission and Pathogenesis of Tuberculosis  
As stated earlier, the bacterial disease, tuberculosis (TB) is transmitted when the patients 
who have pulmonary TB expelled the droplet nuclei through cough, sneeze, and even 
speak (Brewer and Heymann, 2004; Bjune, 2005; Gandy & Zumla, 2002). A droplet 
nucleus sized 10 μm can carry from 1 to 10 tubercle bacilli. On the other hand, tubercle 
bacilli particles get suspended in the air due to coughing or sneezing and are accordingly 
transported by the air currents which can carry them in the air for a long time and spread 
them all the way through rooms or buildings. Bacilli that are more likely to be inhaled 
are very often settled in the upper airways (American Thoracic Society 2000). It was 
reported that the most effective particles of droplet nucleus that can spread tuberculosis 
from person to another one are those sized 5 μm or less in diameter. Though small, they 
can still produce the anchorage in bronchioles and respiratory alveoli due to their ability 
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to avoid the mucus and ciliary’s system action. Its small size helps them to remain 
suspended in the air for quite long periods of time. (Palomino et al., 2007; Friedman, 
2001; WHO 1999). 
 
Transmission of TB happens with high prevalence in crowded places with either none or 
bad ventilation (Hawker et al., 1999; Beggs et al., 2003; Elender et al., 1998 and Valin et 
al., 2005).   A sputum smear-positive person having a pulmonary TB is four to six times 
more contagious than a smear-negative case (Menzies et al., 1999). On the other hand, 
sputum smear-negative culture-positive patients with pulmonary TB are still contagious 
to others too (Hernandez-Garduno, 2004; Behr et al., 1999).  According to Jerant et al. 
(2000) and WHO (1999), environmental factors that best suit TB transmissions include 
the following: 
1. Vulnerable individuals getting exposed to a contagious person in a relatively small, 
enclosed space, 
2. Insufficient ventilation which may result in either poor dilution or in the removal of 
infectious droplet nuclei,  
3. Air recirculation containing contagious droplet nuclei  
4. Duration of disclosure, and  
5. Susceptibility of the exposed person. 
 
After inhalation, the droplet nucleus is passed down the bronchial tree, and implants in a 
respiratory bronchiole or alveolus. When inhaling tubercle bacillus, the tubercle creates 
an infection in the lung which relies on both the bacterial malignancy and the intrinsic 
microbicidal capability of the alveolar macrophage that ingests it. Bacteria can then 
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develop within the alveolar macrophage if they’re capable to stay alive in its initial 
resistance.  
The approximate dividing of tuberculosis bacteria, which grows slowly, happens every 
25 to 32 hours within the macrophage (American Thoracic Society, 1999). Responses of 
two distinct T cell-mediated immune begin at 2-4 weeks. A reaction to a delayed-type 
hypersensitivity demolishes non activated macrophages including bacilli but leads to 
tissues necrosis and caseation. 
 
Cell mediated immunity ends in microphages being activated into epithelioid cells with 
granulomas formation seen at the periphery of the caseation. A flexible organism, one 
that is able to multiple quickly external cells within cavities, survives inside macrophage 
and stops fusion between the lysosome and phagosome, and it also survive in relatively 
inactive state with only rare ruptures of division. Primary complex heals spontaneously 
in 1-2 months in 85-90% of cases and the tuberculin skin test becomes positive (Haslett, 
et al. 2002). Multiplication of M. tuberculosis is not enclosed in 10-15%, and that either 
local pressure effects, lymphatic extends to the pleura or pericardium, and ruptures into 
adjacent bronchus or pulmonary blood vessels happen due to lymph node enlargement. 
 
In places where dissemination had arisen, the disease may develop fast to the evolution 
of miliary and meningeal tuberculosis. Furthermore, infection of foci can be set up in the 
bone, the lung, the genitourinary and gastrointestinal tracts, or lymph nodes, which may 
develop into a clinical disease. However, 85-90% of patients develop latent infection 
(positive tuberculin test or radiographic evidence of self-healed tuberculosis) 5-10% of 
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them reactivate during their life-time, resulting in post-primary disease. This is 
predominantly pulmonary (75%) and infectious (50% smear-positive). 
  
Post-primary disease can result from the re-exposure to smear positive pulmonary 
tuberculosis and accordingly accounts for up to one-third of all cases. The possibility of 
infection after exposure is 30%, development of progressive primary disease is 30% and 
re-infection from other infectious cases is 50% and all these possibilities are increased in 
HIV of infected individuals.  Further, where good immune function is retained in HIV, 
clinical disease resembles classical post-primary tuberculosis. However, where 
significant immunodeficiency has occurred, the presentation is more likely to be 
disseminated or extra pulmonary (Haslett, et al. 2002; Friedman 2001; and Mario et al.  
2008).  
 
1.4 Diagnosis of Tuberculosis 
For proper and complete medical evaluation of TB diagnosis, the following steps have to 
be taken into consideration: 
 
1.4.1 Determining the Medical History  
One should obtain from the patient a complete history of the possible exposures to 
people with TB, Multidrug-Resistant TB (MDR-TB), past history of TB, previous 
positive tuberculin skin test, and previous history of treatment either for TB infection or 
any disease. An adequate clinical history should include information about household, 
immigration from high prevalence area, and about the medical factors which motivate 
factors for TB disease (e.g. diabetes mellitus, HIV infection, injection drug users and 
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homeless people) (American Thoracic Society/Centers for Disease Control and 
Prevention (2003), Correa (1997), Feja and Saiman (2005), Jacobs and Starke (1993), 
Taylor et al. (2005), Vallejo et al. (1994)). 
 
1.4.2 Examining the Physical Symptoms 
Physical examination is an essential part in evaluating, and obtaining the history of 
clinical signs and symptoms of pulmonary TB, which may include prolonged and 
productive coughs over two weeks duration, hoarseness, chest pain, or hemoptysis. 
Systemic symptoms of TB may involve unexplainable weight loss, fever, night sweats, 
appetite loss, easy fatigability, or chills. 
 
1.4.3 Examining the Bacteriological Aspect  
Such a step implies adopting the following examinations of: 
1.4.3 (a) Sputum Smear 
Bacteriological examination of sputum is referred to as acid fast bacilli (AFB). Such an 
examination is considered the only way in which the diagnosis of pulmonary tuberculosis 
can be confirmed. Whenever tuberculosis is suspected, three specimens of sputum should, 
at least, be collected and examined by microscopy and the examined samples will 
preferably be obtained within two days. 
 
1.4.3 (b) Sputum Culture 
Holtz et al. (2006) stated that the culture of tubercle bacilli is regarded as a confirmation 
step that is necessary for carrying out the sensitivity test which is in turn is essential for 
monitoring the initial and acquired drug resistance to anti-tuberculosis drugs. 
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1.4.4 Examining TB Radiographically  
Chest x-ray screening has been used for active case finding for the last seventy years 
Golub et al. (2005), WHO (1994) and Friedman (2001), mentioned that the x-ray 
diagnosis of tuberculosis is unreliable because other chest diseases may resemble 
tuberculosis on x-ray, and because pulmonary TB may show many forms of 
radiographic abnormalities. 
 
1.4.5 Tuberculin Skin Test (TST) 
Tuberculin Skin Test is used to detect the M. tuberculosis infection in people who do not 
show symptoms of tuberculosis. Passalent et al. (2007) stated that the Mantoux test is a 
favored method for tuberculin skin test since the test depends on the M. tuberculosis 
infection produce hypersensitivity reaction to antigenic component of the organism. In 
order for an immune response to the test to be developed in a person, it generally takes 
2-10 weeks after tuberculosis infection. Both false-positive and false-negative results 
occur. The reactions of false-positive tuberculin skin test occur in persons who were 
previously vaccinated against M. tuberculosis with BCG as well as those infected with 
non tuberculosis mycobacteria. On the other hand, reactions of false-negative tuberculin 
skin test may result from improper testing technique, concurrent infections, malnutrition, 
advanced age, immunological disorders, lymph reticular malignancies, corticosteroid 
therapy chronic renal failure, HIV infection and fulminant tuberculosis. When testing 
individuals with latent tuberculosis infection, they may have negative skin test reaction 
many years after infection.  
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1.5 Treatment of Tuberculosis  
Two aims for treatment from tuberculosis; the first one prevents tuberculosis 
transmission by rendering the patients non-infectious and the second is to prevent 
morbidity and death by curing tuberculosis patients. 
  
1.5.1 Treatment of Latent Tuberculosis Infection (LTBI) 
The necessity lies in treating persons with latent tuberculosis infection which is actually 
to prevent and control the development of active disease in the future, also called as 
preventive therapy or chemoprophylaxis. Generally, those applying for treatment of 
latent TB are identified by the TST of persons in high-risk groups. In a period of six to 
nine months, isoniazid is administered (10 mg/kg/day or, at most, 300 mg/day) in every 
adult person vulnerable to develop an active disease (Robert, et al. 2002; Horsburgh, 
2004; Castelo-Filho et al., 2004; Hopewell et al., 2006).  
 
Such treatment reduces the risk of infection progress to active diseases, yet it does not 
keep the patient from exogenous exposure. The candidates for treating latent TB 
infection are those close to active pulmonary TB patients, persons who usually are in 
close contacts with active pulmonary TB patients (AFB smear-positive),  persons with 
TST change (appositive test with  >10 mm in period after a formerly negative test that 
has been applied earlier. In addition, for immunosuppressed persons (HIV) who have 
positive TST of > 5 mm, the treatment has been also applied. Other candidates are also 
those who are in close contact with immunosuppressed persons with a smear-positive 
TB patient. Moreover, persons with a chest X-ray image steady of residual TB, and 
without a history of previous anti-TB remedy are also close to active pulmonary. 
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Generally, medical doctors should confirm the absence of an active TB disease before 
starting the preventive chemotherapy with isoniazid. Initial steps can be taken by 
noticing the following: Chest X-ray is to be normal; and individual is to be 
asymptomatic and should exclude active TB, either pulmonary or extra pulmonary, 
particularly, in patients with moderate/severe immunodeficiency before beginning with 
the preventive chemotherapy. Furthermore, patient appropriate follow-up is necessary to 
make sure the supplement of a regular drug and at least 70% adherence to the preventive 
treatment regimen. 
 
1.5.2 Treatment Regimens 
Standard short course regimens are divided into an initial or bactericidal, phase and 
continuation or sterilization phase. Through the initial phase, the greater part of the 
tubercle bacilli are destroyed; symptoms resolve, and generally the patient become non-
infectious. The continuation phase is necessary to remove persisting mycobacteria and 
avoid relapse (Toman, 2004; Palomino et al., 2007).    
 
Isoniazid  
Isoniazid is the most widely used anti-tuberculosis drug. It is given in doses of 5 mg per 
kg body weight per day up to maximum 300 mg per day. It can be safely used on 
pregnant women. A major side effect, hepatitis, develops in about 0.5 % of cases, if 
hepatitis is suspected or jaundice is observed, stop treatment (Rieder, 2004; WHO 2009).    
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Rifampicin  
Rifampicin is a very potent, relatively non toxic drug. The daily dose for children and 
adults is 10 mg per kg body weight up to 600 mg per day. It can be safely used on 
pregnant women. When given in recommended dosages, rifampicin dose not cause any 
side effect with great frequency, particularly during continuous daily administration. 
One of the major side effects of rifampicin is hepatitis, although this is rare. Alcoholism, 
pre-existing liver diseases or the simultaneous administration of other hepatotoxic agents 
seem to increase the risk. The development of jaundice requires discontinuation of the 
drug (Rieder, 2004; WHO, 2009).   
   
Pyrazinamide   
Pyrazinamide is most active during the second and third month of therapy. The daily 
dose for adult is 25 mg per kg body weight and for children 20-40 mg per kg body 
weight up to maximum 2500 mg. It may be used safely on pregnant women. The most 
serious side effect of pyrazinamide is hepatitis. Joint pains and occasional attack of gout, 
due to the diminished excretion and accumulation of uric acid may occur less frequently 
(Rieder, 2004; WHO, 2009). 
 
Isoniazid/Thioacetazone 
Thioacetazone may help prevent the emergence of resistance to other drugs such as 
isoniazid, and therefore is administered in combination with isoniazid. The daily dose is 
2.5 mg per kg body weight for adults and children up to maximum of 150 mg per day.  
Hepatitis is the major side effect that occurs as with isoniazid alone. Cutaneous reaction 
in patients treated with medication (due to thioacetazone) may be more serious than 
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other drugs. Exfoliative dermatitis or Stevens-Johnson syndrome may also occur and can 
be fatal.  
 
Streptomycin  
Streptomycin has strong effect on the elimination of tubercle bacilli in cavities of the 
lungs. The daily dose is 15 mg per kg body weight for adult 20 mg per kg body weight 
for children, up to maximum of one gram. The main toxic side effect of streptomycin is 
vestibular damage. The risk increases with the dose and age (Rieder, 2004; WHO, 
2009). 
 
Ethambutol  
The primary use of ethambutol is to prevent emergency of resistance to the drugs. The 
daily dose in the first two months of chemotherapy is 25 mg per kg body weight in 
adults and 15 mg per kg body weight in children. When administered for more than two 
months, the dose should be reduced to 15 mg per kg body weight per day. Ethambutol 
may produce impairment of vision; a decrease in visual acuity, blurring and red-green 
color blindness (Rieder, 2004; WHO, 2009). 
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1.5.3 Regimens  
1.5.3.1 Regimen for Positive Pulmonary  
New cases of AFB smear positive pulmonary tuberculosis and other newly diagnosed 
patients who are seriously ill have severe forms of tuberculosis. The regimen include 
patients with tuberculosis meningitis, disseminated tuberculosis, tuberculosis 
pericarditis, peritonitis bilateral or extensive pleurisy, spinal disease with neurological 
complications, and smear negative pulmonary tuberculosis with extensive parenchymal 
involvement, intestinal or genito-urinary tuberculosis (Harries, 2004; WHO, 2009). 
    
The regimen consists of initial (intensive) phase: 2HRZS(E); i.e., isoniazid, rifampicin, 
pyrazinamide and either streptomycin or ethambutol, given daily under strict direct 
observation for 2 months (8 weeks). When the patient has completed the initial phase of 
2 months and the sputum smear is negative, the continuous phase is initiated. If the 
sputum smear is positive at two months, the initial phase of 4 drugs daily is continued 
for other four weeks under strict observation. After this, the continuation phase is 
initiated, regardless of sputum smear examination results (WHO, 2003). 
 
Continuation phase: 6HT, e.g. isoniazid and thioacetazone daily for six months. For the 
patients who has serious adverse reactions (such as Stevens-Johnson syndrome, 
exfoliative dermatitis) ethambutol may be substituted with thioacetazone.  Patients 
should come to the health facility every four week to collect their drugs for self 
administration at home (Table 1.3).  
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Table 1.3: Regimen for Positive Pulmonary (adapted from WHO, 2003) 
Note: H refers to isoniazid; R refers to rifampicin; Z refers to pyrazinamide; S refers to 
streptomycin; E refers to ethambutol; T refers to thioacetazone. 
 
1.5.3.2 Regimen of Extra Pulmonary and Negative Pulmonary 
Initial intensive phase: 2HTS (E), i.e., isoniazid, thioacetazone and either streptomycin 
or ethambutol, given daily for two months. Patients should come to the health facility 
every month to collect their drugs for self administration at home. Continuation phase: 
10 HT i.e., isoniazid and thioacetazone daily for 10 months (Table 1.4). Patients should 
come to the health facility every month to collect their drugs for self administration at 
home (WHO, 2003).   
Initial intensive phase Continuation 
phase 
     Daily during month 1 and 2 Daily during 
months  
3,4,5,6,7,and 8 
  HR Z S or E HT 
Weight of 
patients (pre 
treatment 
weight 
H+R  
combined tablet 
100mg+150mg 
150mg+300mg 
Z  
tablet 
500mg 
S 
injection 
E   
tablet  
400 mg 
H+RT  
combined tablet 
100mg+50mg 
300mg +150mg 
less than 
33kg 
2 (100mg+150mg) 2 500 mg 2 2 (100mg+50mg) 
33 kg to 50 
kg  
3 (100mg+150) 3 750 mg 2 3 (300mg+150mg) 
51 kg or 
more 
2 (150mg+300mg) 4 1 g 3 2 (300mg+150mg) 
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Table 1.4: Regimen of Extra Pulmonary and Negative Pulmonary (adapted from 
WHO, 2003) 
                     Initial intensive phase Continuation phase 
                                     Daily during month 1 and 2 Daily during months 3- 8   
  HT S HT 
Weight of patients 
(pre treatment weight) 
H 100g T 50 mg 
(combined tablet 
S injection H 100g T 50 mg 
(combined tablet 
less than 10 kg 1/2 0.25 g ½ 
10 kg to 19  kg  1 0.5 g 1 
20 kg 32 2 0.5 g 2 
33 kg to 49 kg 3 0.75 g 3 
50 kg or more 3 1.00g 3 
Note: H refers to isoniazid; S refers to streptomycin; T refers to thioacetazone. 
 
1.5.4 Re-Treatment of TB  
The regimen according to WHO (1997) should be given to patients afflicted with 
tuberculosis diseases after completing the standard regimen (2 months of isoniazid, 
rifampicin, pyrizanamide and streptomycin or ethambutol then 6 months of isoniazid 
and thioacetazone). Re-treating TB involves passing through two phases:   
   
Initial (Intensive Phase): this phase requires using 2HRZES/1HRZE, i.e. rifampicin, 
isoniazid, pyrazinamide and ethambutol, which is supplemented with streptomycin for 
the first two months (Table 1.5). Then, the same drug is used again, but this time without 
streptomycin. The dose should be taken daily for about one month and under strict, 
direct observation. When the patient completes the initial phase which consists of 2 
months and when the sputum smear is negative, the continuous phase is started. If the 
sputum smear is positive throughout the three months, the initial phase of treatment with 
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four daily oral drugs lasts for another four weeks. If the patient is still smear- positive at 
the end of the fourth month, all drugs are stopped for 2-3 days, and a sputum specimen is 
sent to the laboratory for culture and for sensitivity testing. The patient should, then, 
start the continuation phase and refer to a specialist if possible.  
 
Continuation Phase: the second phase demands using 5HRE, i.e., 5 months of isoniazid, 
rifampicin and ethambutol, which are given daily under direct strict observation. If the 
patient remains positive after the completion of the continuation phase, he is no longer 
eligible for this regimen. That is to say, this patient will be considered as a chronic case 
and will be dealt with accordingly.  
 
Table 1.5: Regimen of Re-Treatment of TB (adapted from WHO, 2003) 
Initial intensive phase Continuation phase 
 
   
Daily during month 1 and 2 
 
Daily during months 
3,4,5,6,7,and 8   
  S HR Z E HR E 
Weight of 
patients (pre 
treatment weight 
S 
 
combined tablet 
100 mg+150 mg 
150 mg +300 mg 
tablet 
500mg 
tablet 
400 
mg 
combined 
tablet 100 
mg+ 50 mg 
300 mg + 
150 mg 
400 
mg 
less than 33kg 500 
mg 
2 (100 mg+150 
mg) 
2 2 2 (100mg 
+150 mg) 
2 
33 kg to 50 kg  750 
mg 
3 (100 mg+150 
mg) 
3 2 3 
(100mg +   
150 mg) 
2 
51 kg or more 750 
mg 
2 (150 mg+300 
mg) 
4 3 2 
(150 mg+ 
300 mg) 
3 
Note: H refers to isoniazid; R refers to rifampicin; Z refers to pyrazinamide; S refers to 
streptomycin; E refers to ethambutol. 
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1.5.5 Treatment of Drug-Resistant Tuberculosis  
Patients with drug resistance need careful supervision and management. Most resistance 
was to the effective drugs or at least to rifampicin and isoniazid, anti-TB drugs, or the so 
called multi-drug-resistant TB. Such a process consists of two phases as (WHO, 2010): 
   Initial Phase: this phase involves taking the following for three months: streptomycin, 
kanamycin or amikacin, pyrazinamide, quinolones (ofloxacin or ciprofloxacin), 
ethambutol or cycloserine.– amikacin. 
  Continuation Phase: in this phase three drugs should be used for 18-24 months, such 
asethionamide, quinolone, ethambutol or cycloserin. 
 
1.5.6 Directly Observed Treatment (DOTS) 
Direct observed treatment (DOTS) can improve adherence to treatment as it requires the 
worker to observe the patient when he is swallowing their medication. Around 10 
million infectious patients have been successfully treated under the DOTS programme 
since it was first introduced on a global scale in 1995.  
 
As reported by Sharma and Liu (2006), WHO describes the five fundamental principles 
of DOTS, as follows: 
1. Political commitment and resources 
2. Accurate diagnosis by AFB smear-positive 
3. Standardized short-course treatment for all patients with directly 
observed  
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4. Regular provide with good and adequate free drug, and finally  
5. Monitoring of the outcome of the patients.  
 
In some parts of the world, a supply of 6 months of drugs for DOTS costs less than US$ 
10 per patient. As ranked by the World Bank, the DOTS strategy is one of the “most 
cost-effective of all health interventions”. Furthermore, an expected increase in drug 
resistance can be avoided by countries that employ DOTS such as cases in Cuba and 
Nepal in which levels of drug resistance showed a notable declination (WHO, 1994; 
WHO, 2002c). In 2004, 183 countries and territories implemented the DOTS strategy 
and that 83% of the world’s population lived in DOTS-covered countries in the end of 
2004. 4.4 million new cases were reported by DOTS programs and relapse TB cases in 
2004; 2.1 millions were new AFB smear-positive. A total of 21.5 million TB patients, 
and 10.7 million AFB smear-positive patients were treated in DOTS programs over 10 
years ranging from 1995-2004 (Palomino et al., 2007, Sharma and Liu, 2006, WHO, 
2006a). 
 
Throughout the world, case detection rate by DOTS increased from 11% in 1995 to 
approximately 45% by 2003, and exceeded 50% by the end of 2005. In 2003, DOTS 
treated around 1·8 million new smear-positive cases. This scale went on even in regions 
such as the WHO African region where multiple health crisis usually occurs as DOTS 
case detection rate rose from 24% to 50% during the years 1995 to 2003. DOTS cases 
where accounted the highest in India and China reaching 60% of the total increase of 
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cases in 2003. Furthermore, 20% of the global incidence of tuberculosis found in India 
which still has more cases than any other country. 
 
In fact, the DOTS program showed a dramatic development during the year 1997 until 
early 2005, as it increased from 20 million (less than 2% of the population) to more than 
one billion people (90%) as stated by Revised National Tuberculosis Control Program 
(RNTCP). However, implementation of DOTS in China began in 13 of the 31 mainland 
provinces in 1991 and got coverage of 100% by the middle of 2005.(Dye et al., 2005; 
Frieden and Munsiff, 2005; Sharma and Liu, 2006; WHO, 2006a). However, such 
records were not similar in countries like Africa where the rates of TB continued to rise 
due to major failure of DOTS implementation which registered less than 75% cure rates 
while death rates were as high as 8% in patients co-infected with M. tuberculosis and 
HIV in 2002.  
 
Weak health systems at times of HIV epidemic expansion is considered the major 
problem in Eastern Europe that showed continuing increases in TB occurrence rates 
throughout the 1990s, although the increase now appears to be pointed. This is still 
arguable in the sense that whether this statistic showed a failure of DOTS, or the result 
of the quick spread of the HIV epidemic. On the other hand, death rates in DOTS 
recipients remained stable at 5% in Central Asian countries which caused MDR-TB to 
consider the problem in both Eastern Europe and Central Asia (Dye et al., 2005; Frieden 
and Munsiff, 2005; Sharma and Liu, 2006; and WHO, 2006a). 
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In addition, and in disregards of substantial success with DOTS expansion, many 
countries will not probably meet the UN Millennium Development Goals' target of 
halving the prevalence of tuberculosis and the associated death rates between 1990 and 
2015. Hence, more ground-breaking steps are to be taken as the public-health 
community moves beyond DOTS expansion to global tuberculosis control to better 
control TB globally (Sharma and Liu, 2006).  
 
Yemen witnessed the first implementation of DOTS in 1995 by National Tuberculosis 
Program (NTCP) as a strategy of National TB control all over the country. Yemeni 
government worked to get the policy of the National TB control program (NTCP) in line 
with WHO TB control strategy of the Direct Observed Treatment, short course (DOTS). 
Patients were observed by nurses as they swallowed their medication in the first stage of 
the treatment. Once they missed their appointment, they were phoned to come or they 
were visited to their house by the nurses.  
 
1.5.7 Adherence to TB Treatment  
Consequences of non adherence to antituberculosis medications can be seen as a failure 
to treatment, continued transmission of the tuberculosis and drug resistance 
development. Thus, patients must be treated under directly observed therapy so as to 
ensure adherence and therapy completion (Cabrera et al., 2002 and Oza, 2002). 
 
Furthermore, patients can be briefed and educated about TB diseases, methods of 
diagnosis, ways of transmission, treatment and prevention in order to improve the 
adherence to treatment (Cabrera et al., 2002). 
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1.6 Study Problem Statement  
Tuberculosis is a major public health problem both in worldwide and Yemen. 
Tuberculosis disease forms significant portions of infectious disease and ranks second 
only to HIV/AIDS as a cause of infectious disease deaths (WHO 2004). No studies or 
even reports, on the cost of tuberculosis treatment and HRQoL have been conducted in 
Yemen. Yemen is considered as one of the high burden countries in the region for a long 
time based on the evaluation of TB which has been conducted by National-Wide Survey 
of the Tuberculin Testing among children school (AL-Absi, 2007, AL-Absi, 2010). 
Annual risk factor of TB infection in Yemen is 0.9% and prevalence 8.2 from total 
population (AL-Kamaly, 2006). Furthermore, tuberculosis patients face many problems 
related to physiological, psychological, financial and social problems. All of these 
problems have a great impact on their quality of life of TB patients (Dhingra and Rajpal, 
2003).  
 
1.7 Rational and Importance of Study  
This quantitative study was planned and done to estimate the public health expenditures 
on tuberculosis treatments and to assess the HRQoL of pulmonary and extra pulmonary 
patients by interviewing the patients and health providers in medical centers in Sana’a, 
Yemen. This research seeks to invest its results by using an effective and accurate 
financial policy for the tuberculosis control. It may also help in the assessment of 
economic burden of tuberculosis in the capital city of Sana’a in several ways, such as 
allocation of resources and sets of priorities for tuberculosis control activities, giving 
estimation for the total budget needed for National Tuberculosis Control Programme and 
encouraging the health authorities to pay for prevention and early detection of 
